The estrogenic component of tibolone reduces adiposity in female aromatase knockout mice

Menopause

Volumn 16, Issue 3, 2009, Pages 582-588

  Van Sinderen, Michelle L ^a,b   Boon, Wah Chin ^a,b,c   Ederveen, Antwan G H ^d   Kloosterboer, Helenius J ^d   Simpson, Evan R ^a   Jones, Margaret E E ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adiposity; Aromatase; Estrogen; Progesterone.; Testosterone; Tibolone

Indexed keywords

16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; ANDROSTANOLONE; AROMATASE; CHOLESTEROL; ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TIBOLONE; TRIACYLGLYCEROL;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL COUNT; CELL VOLUME; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; ESTROGEN ACTIVITY; FEMALE; HYPOPHYSIS; LIPOPROTEIN BLOOD LEVEL; MOUSE; NONHUMAN; OBESITY; TRIACYLGLYCEROL BLOOD LEVEL; UTERUS WEIGHT;

ADIPOSITY; ANABOLIC AGENTS; ANIMALS; AROMATASE; FEMALE; MICE; MICE, KNOCKOUT; NORPREGNENES; OVARIECTOMY;

EID: 67649863809     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31818fb20b     Document Type: Article

References (41)

1. Kloosterboer H. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004;48:S30-S40.
2. Kloosterboer H. Tibolone: a steroid with a tissue specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-238.
3. Kloosterboer H. Tibolone and its metabolites: pharmacology, tissue specificity and effects in animal models of tumors. Gynecol Endocrinol 1997;11:63-68.
4. Modelska K, Cummings G. Tibolone for postmenopausal women: systematic review of randomised trials. J Clin Endocrinol Metab 2002; 87:16-23.
5. DeGooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003;68:21-30.
6. DeGooyer ME, Kleyn GT, Smits KC, Ederveen AG, Verheul HA, Kloosterboer HJ. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183:55-62.
7. Reed M, Kloosterboer H. Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas 2004;48:S4-S6.
8. Raobaikady B, Parsons MF, Reed MJ, Purohit A. Tibolone and its delta-4,7α-methyl norethisterone metabolite are reversible inhibitors of human aromatase. J Steroid Biochem Mol Biol 2007;104:154-160.
9. Falany J, Falany C. Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene. J Steroid Biochem Mol Biol 2007;107:202-210.
10. Wang M, Ebmeier CC, Olin JR, Anderson RJ. Sulfation of tibolone metabolites by human postmenopausal liver and small intestinal sulfotransferases (SULTs). Steroids 2006;71:343-351.
11. Verheul H, van Jersel ML, Delbressine LP, Kloosterboer HJ. Selective tissue distribution of tibolone metabolites in mature ovariectomised female cynomolgus monkeys after multiple doses of tibolone. Drug Metab Dispos 2007;35:1105-1111.
12. Gower B, Muñoz J, Desmond R, Hilario-Hailey T, J lao X. Changes in intra-abdominal fat in early postmenopausal women: effects of hormone use. Obesity 2006;14:1046-1055.
13. Jones ME, Thorbum AW, Britt KL, et al. Aromatase deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A 2000;97:12735-12740.
14. Misso ME, Murato Y, Boor WC, Jones ME, Britt KL, Simpson ER. Cellular and molecular characterisation of the adipose pheno-type of the aromatase deficient mouse. Endocrinology 2003;144: 1474-1480.
15. Brodie A. Recent advances in studies of estrogen biosynthesis. J Endocrinol Invest 1979;2:445-460.
16. Fisher CR, Graves KH, Parlow AF, Simpson ER. Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the cyp19 gene. Proc Natl Acad Sci U S A 1998;95:6965-6970.
17. Simpson ER, Misso M, Hewitt KN, et al. Estrogen - the good, the bad and the unexpected. Endocr Rev 2005;26:322-330.
18. Jones ME, McInnes KJ, Boon WC, Simpson ER. Estrogen and adiposity - utilizing models of aromatase deficiency to explore the relationship. J Steroid Biochem Mol Biol 2007;106:3-7.
19. Jones ME, Boon WC, Proeitto J, Simpson ER. Of mice and men: the evolving phenotype of aromatase deficiency. Trends Endocrinol Metab 2006;17:53-62.
20. Misso ML, Hewitt KN, Boon WC, et al. Cholesterol feeding prevents adiposity in the obese female aromatase knockout (ArKO) mouse. Horm Metab Res 2005;37:26-31.
21. Jones ME, Thorbum AW, Britt KL, et al. Aromatase-deficient (ArKO) mice accumulate excess adipose tissue. J Steroid Biochem Mol Biol 2001;79:3-9.
22. Anandaraja S, Narang R, Godeswar R, Laksmy R, Talwar KK. Low-density lipoprotein cholesterol estimation by a new formula in Indian population. Int J Cardiol 2005;102:117-120.
23. Yan M, Jones ME, Hernandez M, Liu D, Simpson ER, Chen C. Oestrogen replacement in vivo rescues the dysfunction of pituitary somatotropes in ovariectomised aromatase knockout mice. Neuroendocrinology 2005;81:158-166.
24. Massinis IE. Ovarian feedback, mechanism of action and possible clinical implications. Hum Reprod 2006;12:557-571.
25. McInnes KJ, Corbould A, Simpson ER, Jones ME. Regulation of adenosine 5′-monophosphate-activated protein kinase and lipogenesis by androgens contributes to visceral obesity in an estrogen deficient state. Endocrinology 2006;147:5907-5913.
26. Slayden O, Brenner R. Hormonal regulation and localization of estrogen, progestin and androgen receptors in the endometrium of nonhuman primates: effects of progesterone receptor antagonists. Arch Histol Cytol 2004;67:393-409.
27. Tommaselli GA, Di Carlo C, Di Spiezio Sandro A, et al. Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene. Menopause 2006;13:660-668.
28. Odabasi AR, Yuksel H, Kafkas S, et al. Effects of tibolone on abdominal subcutaneous fat, serum leptin levels, and anthropometric indices: a 6-month, prospective, randomized, placebo-controlled, double-blind study. Adv Ther 2006;23:926-937.
29. Hewitt KCN, Boon WC, Muvata Y, Jones ME, Simpson ER. The aromatase knockout mouse presents with a sexually dimorphic disruption to cholesterol homeostasis. Endocrinology 2003;144:3895-3903.
30. Cagnacci A, Mallas E, Tuveri F. Effect of tibolone on glucose and lipid metabolism in postmenopausal women J Clin Endocrinol Metab 1997; 82:251-253.
31. Morris E, Denton E, Robinson J. High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure. Climacteric 1999;2: 13-20.
32. Britt KL, Drummond AE, Cox VA, et al. An age related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene. Endocrinology 2000;141:2614-2623.
33. Giustina A, Veldhuis J. Pathophysiology of the neuroregulation of GH secretion in experimental animals and humans. Endocr Rev 1998;19: 717-797.
34. Veldhuis JD, Anderson SM, Kok P, et al. Estradiol supplementation modulates growth hormone (GH) secretory-burst waveform and recombinant human insulin like growth factor-1- enforced suppression of endogenously driven GH release in postmenopausal women. J Clin Endocrinol Metab 2004;89:1312-1318.
35. Jacobsen DCE, Samson MM, Kezic S, Verhaar HJ. Postmenopausal HRT and tibolone in relation to muscle strength and body composition. Maturitas 2007;58:7-18.
36. Genazzani AD, Gamba O, Nappi L, Volpe A, Petraglia F. Modulatory effects of a synthetic steroid (tibolone) and estradiol on spontaneous and GH-RH induced GH secretion in postmenopausal women. Maturitas 1997;28:27-33.
37. Toda K, Takeda K, Okada T, et al. Targeted disruption of the aromatase P450 gene (Cyp19) in mice and their ovarian and uterine responses to 17A-oestradiol. J Endocrinol 2001;170:99-111.
38. Blom MJ, Wassink MG, De Gooyer ME, et al. Metabolism of tibolone and its metabolites in uterine and vaginal tissue of rats and human origin. J Steroid Biochem Mol Biol 2006;101:42-49.
39. Schatz F, Kuczynski E, Kloosterhoer HJ, et al. Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: evidence of progestogenic effect. Steroids 2005;70:840-845.
40. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metabol 2007;92:911-918.
41. Hanifi-Moghaddam P, Gielen SC, Kloosterboer HJ, et al. Molecular portrait of the progestogenic and estrogenic actions of tibolone: behaviour of cellular networks in response to tibolone. J Clin Endocrinol Metab 2005;90:973-983.